Cargando…
Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
Autor principal: | Fukaya, Hidehira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411187/ https://www.ncbi.nlm.nih.gov/pubmed/32782634 http://dx.doi.org/10.1002/joa3.12374 |
Ejemplares similares
-
Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
por: Naito, Kazuya, et al.
Publicado: (2020) -
Safety of catheter ablation of atrial fibrillation without pre‐ or peri‐procedural imaging for the detection of left atrial thrombus in the era of uninterrupted anticoagulation
por: Efremidis, Michael, et al.
Publicado: (2020) -
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019) -
Uninterrupted dabigatran is safer than warfarin in patients undergoing
ablation for atrial fibrillation
por: Spartalis, Michael, et al.
Publicado: (2017) -
Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)